Drug-eluting stents successfully treat vein-graft disease

October 17, 2005

(BETHESDA, MD)--The use of medicated stents markedly improves the clinical outcomes of patients who develop blockages in aging veins surgically grafted onto the heart, according to a just-published study in the November 2005 issue of Catheterization and Cardiovascular Interventions: Journal of the Society for Cardiovascular Angiography and Interventions.

The study found that, compared to conventional bare metal stents, drug-eluting stents significantly cut the rates of heart attack and repeat procedures, both of which are indicators of renarrowing--or restenosis--within the stent.

"There was a fourfold reduction in the incidence of restenosis with the medicated stents," said Dr. Raj Makkar, codirector of the Cardiovascular Intervention Center at Cedars Sinai Medical Center in Los Angeles. "At least over the short term, that's very encouraging."

Drug-eluting stents slowly release medication that prevents the overgrowth of scar tissue inside the stent, and have been shown to significantly reduce the risk of restenosis in the natural arteries of the heart. Treating worn and diseased vein grafts is more challenging, however. In fact, within 5 to 10 years, half of all vein grafts become diseased, necessitating either stenting or repeat bypass surgery in some cases.

The study analyzed data from 223 consecutive patients who had a stenting procedure to restore blood flow through clogged vein grafts, 139 of whom were treated with a drug-eluting stent and 84 of whom were treated with a bare metal stent. Patients had undergone the original bypass surgery an average of nearly 8 years earlier.

During 9 months of follow-up, 4 percent of patients treated with a drug-eluting stent experienced a heart attack, as compared to 20 percent of patients treated with a bare metal stent. Similarly, 10 percent of patients treated with a drug-eluting stent needed a repeat procedure to reopen the vein graft, as compared to 37 percent of patients treated with bare metal stents. The combined rates of heart attack, repeat procedure, and death were 10 percent and 37 percent, respectively.

The Cedars Sinai researchers are continuing to follow-up patients to determine whether drug-eluting stents offer a similar advantage over the long run. Since plaque tends to build up throughout vein grafts, patients may develop new blockages that require additional stenting procedures.

"We can't expect drug-eluting stents to eliminate all problems with bypass grafts, but this study suggests it is reasonable to use medicated stents to treat these patients," Dr. Makkar said.
-end-
Headquartered in Bethesda, Md., the Society for Cardiovascular Angiography and Interventions is a 3,400-member professional organization representing invasive and interventional cardiologists. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI was organized in 1976 under the guidance of Drs. F. Mason Sones and Melvin P. Judkins. The first SCAI Annual Scientific Sessions were held in Chicago in 1978.

Society for Cardiovascular Angiography and Interventions

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.